CMS plans a voluntary pilot model that would let Medicare Part D plans and participating state Medicaid programs cover GLP‑1 drugs for weight management, a threshold event for obesity drug access. The Centers for Medicare & Medicaid Services framed the test as a way to expand coverage while assessing budgetary effects and utilization patterns. If adopted at scale, the model could materially widen patient access to GLP‑1 therapies among seniors and low‑income populations and reshape formulary strategy for manufacturers and payers. The pilot’s design, participation rules and duration will determine how quickly plan sponsors and state Medicaid programs adjust coverage and prior‑authorization frameworks.